Related coverage linked through entity extraction aliases.
Jul 20, 2026
Phase III trial dropout rates have doubled and protocol deviations rose 184%, underscoring patient recruitment and retention as key derisking levers. The recruitment services market is projected to reach $5.69 billion by 2030.
Mar 16, 2026
Two phase 3 trials demonstrate significant improvements in skin clearance and disease severity for children and adolescents with moderate-to-severe atopic dermatitis treated with targeted biologics.
Mar 04, 2026
The alopecia areata treatment market is projected to grow significantly through 2036, driven by rising prevalence and the anticipated launch of emerging therapies including JAK inhibitors and novel drug classes targeting immune pathways.
